Bonnie Weiss McLeod

Cooley advised Jazz Pharmaceuticals on its $1.5 billion acquisition of Celator. The transaction adds the orphan drug VYXEOS which aims to treat AML. Jazz Pharmaceuticals, a Cooley client since 2006, is an international biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing meaningful products that address unmet medical needs.

Few patent cases make it all the way to the Supreme Court. Even fewer involve a dispute in which a company's very survival is at stake. Since 2011, our client Gevo, a pioneer in the biofuels industry, and Butamax, a joint venture of giants BP and DuPont, had been trading blows, filing close to a dozen patent suits against each other. Butamax initially brought suit in the District of Delaware in an attempt to knock Gevo out of the emerging market for isobutanol alternative energy. In that case, the court granted summary judgment of noninfringement in favor of Gevo, prompting Butamax to appeal. On appeal, the Federal Circuit rejected the district court's claim construction and issued a new claim construction that vacated the noninfringement ruling.

In response, Cooley took the case to the US Supreme Court and, in January 2015, the high court granted our petition for writ of certiorari, vacating the judgment against Gevo and remanding the case back to the Federal Circuit for further consideration. This decision, and numerous other victories including key summary judgment victories, paved the path for Gevo to reach a favorable global patent cross-license and settlement agreement with Butamax. The agreement forms a partnership between the two biofuel companies aimed at leveraging one another's technology.

Cooley handles ongoing patent counseling and prosecution work for Native Microbials, helping to build its global patent portfolio, including obtaining key US patents covering various microbial products for improving animal health and patents protecting the company’s process for identifying microbial strains. Native Microbials’ patented platform for microbial identification transforms the analysis of microbial community systems away from the ubiquitous statistically predictive approach practiced today, to a more biologically relevant and functionally descriptive approach, which is yielding industry leading insights into microbial solutions for animal health.

In addition, Cooley recently advised the company on its $46 million Series B financing round.

Cooley advised the underwriters on Vascular Biogenics' initial public offering. Vascular Biogenics is an Israel-based clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of first-in-class treatments for cancer and immune-inflammatory diseases. The company now trades on the Nasdaq Global Stock Market under the symbol "VBLT."

Deutsche Bank Securities acted as the sole book running manager for the offering. JMP Securities and Oppenheimer & Co. acted as co-managers for the offering.

Palo Alto, Calif. – Cooley achieved a major victory when it secured a judgment of no infringement on behalf of leading renewable chemicals and advanced biofuels client Gevo in a patent suit brought by Butamax Advanced Biofuels, a joint venture between BP and DuPont.

On March 19, 2013, a Delaware federal judge issued a favorable claim construction ruling for Gevo, granting Gevo partial summary judgment of no infringement under the doctrine of equivalents, and ruling that two key claims of the Butamax patents were invalid. Although the Court did not grant summary judgment of no literal infringement, Butamax acknowledged that it could not prove literal infringement under the court's claim construction and agreed to stipulate to a judgment of no literal infringement.

In January 2011, Butamax filed a patent infringement suit against Gevo asserting two patents relating to the production of isobutanol, a four-carbon alcohol, in microorganisms. Gevo produces its isobutanol using proprietary recombinant yeast that is genetically engineered to produce it at a high yield. In June 2012, the court denied Butamax's request for a preliminary injunction against Gevo, a decision that was upheld by the US Court of Appeals for the Federal Circuit in December 2012. A trial date was set for early April 2013.

"This judgment marks yet another great step forward for Gevo," said Jim Brogan, partner and chair of the intellectual property group."The ruling enables this highly innovative company to continue to focus on its growth and the development of innovative biofuels products."

A separate patent re-examination team has obtained rejections of all challenged claims of the two asserted Butamax patents from the US Patent and Trademark Office.